The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2022 | BET inhibition as a novel targeted therapy for myelofibrosis
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the promise of BET inhibition as a novel targeted therapy in patients with myelofibrosis (MF). Dr Masarova first highlights some findings from the MANIFEST trial (NCT02158858), evaluating the safety and efficacy of pelabresib, a BET inhibitor, in combination with ruxolitinib in patients with MF. Dr Masarova then discusses the ongoing MANIFEST-2 trial (NCT04603495), and concludes by highlighting various ways of incorporating pelabresib in MF treatment. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
